Alpaslan TANOĞLU, Fatih ÖZÇELİK, Fatih HACIMUSTAFAOĞLU

Modulatory effect of resveratrol and melatonin on natural killer cell activity and adrenomedullin in diabetic rats

Background/aim: Epidemiological evidence suggests that diabetes poses a high risk for many chronic diseases, especially cardiovascular diseases, and cancer by stimulating many inflammatory and immunological pathogenic mediators and affecting natural killer (NK)-cell activity. In this study, the effects of melatonin and resveratrol on IL-6, TNF-alpha, oxidant/antioxidant capacity, NK-cell activity, and mid-regional proadrenomedullin (MR-proADM) levels of diabetic rats were investigated. Materials and methods: In the study, 28 Sprague Dawley rats were randomly divided into the control group (group I) and 3 streptozotocininduced diabetes mellitus (DM) groups (group II, III, and IV), each group consisting of 7 rats. Five mg/kg/day melatonin to group III and 5 mg/kg/day resveratrol (intraperitoneal) to group IV was given. At the end of 3 weeks, NK-cell activity, total antioxidant/oxidant capacity, MR-proADM, IL-6, and TNF-alpha levels were measured in intracardiac blood taken under anesthesia. Results: NK-cell activity of group II was found lower than group I, group III, and group IV (7.4 ± 2.0 vs. 22.5 ± 11.9, 30.6 ± 22.5 and 20.4 ± 9.1 pg/mL; p = 0.0018, respectively). The difference was more prominent in diabetic rats receiving melatonin (p < 0.01). TNF-alpha levels of group II were higher than the group I (p < 0.05). The MR-proADM levels of group II were found to be lower than the group I and group III (6.4 ± 3.6 vs. 14.4 ± 3.2 and 14.0 ± 4.2 ng/L; p < 0.05, respectively). In addition, NK-cell activity was moderately correlated with MR-proADM (r = 0.5618, p = 0.0019). Conclusion: Resveratrol and, more effectively, melatonin modulate by reversing the adverse effects of diabetes on NK-cell activity, which has a protective function in inflammatory and immunological processes. In this modulation, melatonin also acts through adrenomedullin.

PDF

___

1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33 (7): 1674-1685. doi: 10.2337/dc10-0666
2. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G et al. The role of inflammation in diabetes: current concepts and future perspectives. European Cardiology Review 2019; 14 (1): 50-59. doi: 10.15420/ ecr.2018.33.1
3. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319 (6055): 675-678. doi: 10.1038/319675a0
4. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331 (6013): 44-49. doi: 10.1126/ science.1198687
5. Piątkiewicz P, Bernat-Karpińska M, Miłek T, Rabijewski M, Rosiak E. NK cell count and glucotransporter 4 (GLUT4) expression in subjects with type 2 diabetes and colon cancer. Diabetology & Metabolic Syndrome 2016; 8: 38. doi: 10.1186/ s13098-016-0152-6
6. Yoshimoto T, Fukai N, Sato R, Sugiyama T, Ozawa N et al. Antioxidant effect of adrenomedullin on angiotensin IIinduced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology 2004; 145 (7): 3331-3337. doi: 10.1210/en.2003-1583
7. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biology and Medicine 2010; 49 (11): 1603-1616. doi: 10.1016/j.freeradbiomed.2010.09.006
8. Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A et al. Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology 2015; 146 (1): 173-183. doi: 10.1111/imm.12494
9. López-Burillo S, Tan D-X, Mayo JC, Sainz RM, Manchester LC, Reiter RJ. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and α-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. Journal of Pineal Research 2003; 34 (4): 269-277. doi: 10.1034/j.1600-079X.2003.00041.x
10. Aktaş HS, Ozel Y, Ahmad S, Pençe HH, Ayaz-Adakul B et al. Protective effects of resveratrol on hepatic ischemia reperfusion injury in streptozotocin-induced diabetic rats. Molecular and Cellular Biochemistry 2019; 460 (1-2): 217-224. doi: 10.1007/ s11010-019-03582-z
11. Khorsand M, Akmali M, Akhzari M. Efficacy of melatonin in restoring the antioxidant status in the lens of diabetic rats induced by streptozotocin. Journal of Diabetes & Metabolic Disorders 2019; 18 (2): 543-549. doi: 10.1007/s40200-019- 00445-8
12. Kazıkdaş K, Güneli E, Tuğyan K, Erbil G, Küme T et al. The effect of melatonin on experimentally-induced myringosclerosis in rats. Kulak Burun Bogaz Ihtisas Dergisi 2010; 20 (6): 299-304
13. Prabhakar O. Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory effects in diabetic rats. Naunyn-Schmiedeberg’s Archives of Pharmacology 2013; 386 (8): 705-710. doi: 10.1007/s00210-013-0871-2
14. Shoelson SE. Inflammation and insulin resistance. Journal of Clinical Investigation 2006; 116 (7): 1793-1801. doi: 10.1172/ JCI29069
15. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F et al. Human natural killer cells: origin, receptors, function, and clinical applications. International Archives of Allergy and Immunology 2014; 164 (4): 253-264. doi: 10.1159/000365632
16. Caligiuri MA. Human natural killer cells. Blood 2008; 112 (3): 461-469. doi: 10.1182/blood-2007-09-077438
17. Rodacki M, Svoren B, Butty V, Besse W, Laffel L et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007; 56 (1): 177-185. doi: 10.2337/db06-0493
18. Grudzien M, Rapak A. Effect of natural compounds on NK cell activation. Journal of Immunology Research 2018. doi: 10.1155/2018/4868417
19. Piątkiewicz P, Czech A, Tatoń J. Glucose transport in human peripheral blood lymphocytes influenced by type 2 diabetes mellitus. Archivum Immunologiae et Therapiae Experimentalis 2007; 55 (2): 119-126. doi: 10.1007/s00005-007-0015-9
20. Leischner C, Burkard M, Pfeiffer MM, Lauer UM, Busch C, Venturelli S. Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment. Nutrition Journal 2015; 15 (1): 47. doi: 0.1186/s12937-016-0167-8
21. Vallianou NG, Evangelopoulos A, Kazazis C. Resveratrol and diabetes. The Review of Diabetic Studies 2013; 10 (4): 236-242. doi: 10.1900/RDS.2013.10.236
22. Walker JM, Eckardt P, Aleman JO, Da Rosa JC, Liang Y et al. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: a pilot randomized, placebo controlled clinical trial. Journal of Clinical and Translational Research 2018; 4 (2): 122- 135. doi.org/10.18053/jctres.04.201802.004
23. Kimura Y, Okuda H. Resveratrol ısolated from polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in lewis lung carcinoma-bearing mice. The Journal of Nutrition 2001; 131 (6): 1844-1849. doi.org/10.1093/jn/131.6.1844
24. Malaguarnera. Influence of resveratrol on the ımmune response. nutrients 2019; 11 (5): 946. doi.org/10.3390/ nu11050946
25. LeRoith D, Novosyadlyy R, Gallagher E, Lann D, Vijayakumar A et al. Obesity and type 2 diabetes are associated with an ıncreased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Experimental and Clinical Endocrinology & Diabetes 2008; 116 Suppl 1: S4–S6. doi.org/10.1055/s-2008-1081488
26. Chahbouni M, Escames G, Venegas C, Sevilla B, García JA et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. Journal of Pineal Research 2010; 48 (3): 282-289. doi.org/10.1111/j.1600- 079X.2010.00752.x
27. Miller SC, Pandi PSR, Esquifino AI, Cardinali DP, Maestroni GJM. The role of melatonin in immuno-enhancement: potential application in cancer. International Journal of Experimental Pathology 2006; 87 (2): 81-87. doi.org/10.1111/ j.0959-9673.2006.00474.x
28. Kor Y, Geyikli I, Keskin M, Akan M. Preliminary study: evaluation of melatonin secretion in children and adolescents with type 1 diabetes mellitus. Indian Journal of Endocrinology and Metabolism 2014; 18 (4): 565-568. doi: 10.4103/2230- 8210.137521
29. Peschke E, Schucht H, Mühlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. Journal of Pineal Research 2010; 49 (4): 373-381. doi: 10.1111/j.1600- 079X.2010.00804.x
30. Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. British Journal of Pharmacology 2018; 175 (16): 3263-3280. doi: 10.1111/bph.13950
31. Borst SE. The role of TNF-α in ınsulin resistance. Endocrine 2004; 23 (2-3): 177-182. doi: 10.1385/ENDO:23:2-3:177
32. Lowe G, Woodward M, Hillis G, Rumley A, Li Q et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2014; 63 (3): 1115-1123. doi: 10.2337/db12-1625
33. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004; 47 (7): 1135-1142. doi: 10.1007/s00125-004-1447-y
34. Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F et al. Inhibition of Natural killer cell cytotoxicity by Interleukin-6: ımplications for the pathogenesis of macrophage activation syndrome. Arthritis & Rheumatology 2015; 67 (11): 3037- 3046. doi: 10.1002/art.39295
35. Ďuračková Z. Some current ınsights into oxidative stress. Physiology Resolution 2010; 59 (4): 459-469. doi: 10.33549/ physiolres.931844
36. Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. British Journal of Pharmacology 2018; 175 (16): 3263-3280. doi: 0.1111/bph.13950
37. Wu R, Feng J, Yang Y, Dai C, Lu A et al. Significance of serum total oxidant/antioxidant status in patients with colorectal cancer. PLOS ONE 2017; 12 (1): e0170003. doi: 10.1371/ journal.pone.0170003
38. Coppock HA, Owji AA, Bloom SR, Smith DM. A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors. Biochemical Journal 1996; 318 ( Pt 1): 241- 245. doi: 10.1042/bj3180241
39. Shimekake Y, Nagata K, Ohta S, Kambayashi Y, Teraoka H et al. Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. Journal of Biological Chemistry 1995; 270 (9): 4412-4417. doi: 10.1074/jbc.270.9.4412
40. Matteo R De, May CN. Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. British Journal of Pharmacology 2003; 140 (8): 1414-1420. doi: 10.1038/ sj.bjp.0705572
41. Shoji H, Minamino N, Kangawa K, Matsuo H. Endotoxin markedly elevates plasma concentration and gene transcription of adrenomedullin in rat. Biochemical and Biophysical Research Communications 1995; 215 (2): 531-537. doi: 10.1006/bbrc.1995.2497
42. Chini EN, Chini CCS, Bolliger C, Jougasaki M, Grande JP et al. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney International 1997; 52 (4): 917-925. doi: 10.1038/ki.1997.413
43. Zhang S-Y, Lv Y, Zhang H, Gao S, Wang T et al. Adrenomedullin 2 improves early obesity-ınduced adipose ınsulin resistance by ınhibiting the class II MHC in adipocytes. Diabetes 2016; 65 (8): 2342-2355. doi: 10.2337/db15-1626